摘要
目的:探讨采用加巴喷丁治疗糖尿病周围神经痛患者的临床疗效及对血清TNF-α、IL-6的影响。结果:选取我院2015年9月~2017年2月78例糖尿病周围神经痛患者,按治疗方案的分为常规组和研究组,各39例。对常规组患者进行常规降血糖治疗,研究组在此基础上给予加巴喷丁进行干预,并将两组患者血清TNF-α、IL-6水平、VAS评分及用药后不良反应发生率进行对比。结果:研究组患者TNF-α、IL-6水平分别为(6.27±1.25)ng·L-1、(5.92±3.47)ng·L-1,显著低于常规组的(9.35±1.40)ng·L-1、(8.43±4.05)ng·L-1,两组对比具有统计学意义,P<0.05;研究组患者VAS评分为(3.72±0.39)分,常规组患者为(7.34±0.40)分,差异具有显著性,P<0.05;研究组患者用药后不良反应发生率为7.69%,显著低于常规组患者的43.59%,两组对比具有统计学意义,P<0.05。结论 :采用加巴喷丁对糖尿病周围神经痛患者进行治疗,可有效降低患者血清TNF-α、IL-6水平,减轻患者疼痛程度,进一步提升临床疗效,且用药安全性较高,具备临床意义与价值。
Objective： To investigate the clinical efficacy of gabapentin in treatment of diabetic peripheral neuropathic pain（DPNP）and its influence on serum TNF-α and IL-6. Methods： 78 DPNP patients in Xinxiang Second People＇s Hospital from September 2015 to February 2017 were selected,and they were divided into routine group and research group by treatment regimens,39 cases in each group.Routine group was given hpyerglycemic therapy,while research group was given gabapentin based on routine group. The levels of serum TNF-α and IL-6,VAS score and incidence of adverse reactions were compared between the two groups. Results： The levels of TNF-α and IL-6 in research group [（6. 27 ± 1. 25） ng·L^（-1）,（5. 92 ± 3. 47） ng·L^（-1）] were lower than routine group [（9. 35 ± 1. 40） ng·L^（-1）,（8. 43 ± 4. 05） ng·L^（-1）]（P 〈0. 05）; The VAS scores of research group and routine group were（3. 72 ± 0. 39） points and（7. 34 ±0. 40） points,with statistical difference（P〈 0. 05）; The incidence of adverse reactions in research group was 7. 69%,which was lower than 43. 59% in routine group（P〈 0. 05）. Conclusion： Gabapentin in treatment of DPNP can effectively decrease the levels of serum TNF-α and IL-6,reduce pain degree,increase clinical efficacy and have higher drug safety,which has clinical significance and value.
出处
《中国药物评价》
2017年第6期439-441,共3页
Chinese Journal of Drug Evaluation
